Prognostic significance of CD151 overexpression in non-small cell lung cancer

Lung Cancer

Volumn 81, Issue 1, 2013, Pages 109-116

  Kwon, Mi Jung ^a   Seo, Jinwon ^a   Kim, Yu Jin ^b   Kwon, Mi Jeong ^c   Choi, Jun Young ^d   Kim, Tae Eun ^d   Lee, Do Hyeong ^d   Park, Sanghui ^e   Shin, Young Kee ^d   Han, Joungho ^f   Choi, Yoon La ^b,f  

^a Hallym University College of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Kyungpook National University   (South Korea)

^d Seoul National University   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adenocarcinoma; CD151; Lung cancer; Prognosis; Squamous cell carcinoma

Indexed keywords

CD151 ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SMOKING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD151; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 84879042983     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.03.014     Document Type: Article

References (32)

1. Colby T.V., Koss M.N., Travis W.D. Carcinoma of the lung: overview, incidence, etiology and screening. Atlas of tumor pathology: tumors of the lower respiratory tract 1995, 91-106. Armed Forces Institute of Pathology, Washington, DC.
2. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics. CA Cancer J Clin 2001, 51:15-36.
3. Jung K.W., Park S., Kong H.J., Won Y.J., Boo Y.K., Shin H.R., et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2006, 25:1113-1121.
4. Jung K.W., Won Y.J., Park S., Kong H.J., Sung J., Shin H.R., et al. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009, 24:995-1003.
5. Hemler M.E. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005, 6:801-811.
6. Saad R.S., Liu Y., Han H., Landreneau R.J., Silverman J.F. Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Mod Pathol 2004, 17:1235-1242.
7. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009, 9:40-55.
8. Yunta M., Lazo P.A. Tetraspanin proteins as organisers of membrane microdomains and signalling complexes. Cell Signal 2003, 15:559-564.
9. Ke A.W., Shi G.M., Zhou J., Wu F.Z., Ding Z.B., Hu M.Y., et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009, 49:491-503.
10. Boucheix C., Tetraspanins Rubinstein E. Cell Mol Life. Science 2001, 58:1189-1205.
11. Testa J.E., Brooks P.C., Lin J.M., Quigley J.P. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 1999, 59:3812-3820.
12. Kwon M.J., Park S., Choi J.Y., Oh E., Kim Y.J., Park Y.H., et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 2012, 106:923-930.
13. Voss M.A., Gordon N., Maloney S., Ganesan R., Ludeman L., McCarthy K., et al. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer 2011, 104:1611-1618.
14. Yoo S.H., Lee K., Chae J.Y., Moon K.C. CD151 expression can predict cancer progression in clear cell renal cell carcinoma. Histopathology 2011, 58:191-197.
15. Suzuki S., Miyazaki T., Tanaka N., Sakai M., Sano A., Inose T., et al. Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness. Ann Surg Oncol 2010, 18:888-893.
16. Huang X.Y., Ke A.W., Shi G.M., Ding Z.B., Devbhandari R.P., Gu F.M., et al. Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer 2010, 116:5440-5451.
17. Lee D, Suh YL, Park TI, Do IG, Seol HJ, Nam DH, et al. Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas. J Surg Oncol; 2012 [Epub ahead of print].
18. Haeuw J.F., Goetsch L., Bailly C., Tetraspanin Corvaia N. CD151 as a target for antibody-based cancer immunotherapy. Biochem Soc Trans 2011, 39:553-558.
19. Lan R., Liu Z., Song Y., Zhang X. Effects of rAAV-CD151 and rAAV-antiCD151 on the migration of human tongue squamous carcinoma cell line Tca8113. J Huazhong Univ Sci Technol Med Sci 2004, 24:556-559.
20. Tokuhara T., Hasegawa H., Hattori N., Ishida H., Taki T., Tachibana S., et al. Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res 2001, 7:4109-4114.
21. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
22. Greene F.L., Page D.L., Fleming I.D. Lung. American Joint Commite on cancer: AJCC cancer staging manual 2002, Springer, New York, 167-177. 6th ed.
23. Park S., Choi Y.L., Sung C.O., An J., Seo J., Ahn M.J., et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 2011, 27:197-207.
24. Tsuta K., Tanabe Y., Yoshida A., Takahashi F., Maeshima A.M., Asamura H., et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol 2011, 6:1190-1199.
25. Stipp C.S., Kolesnikova T.V., Hemler M.E. EWI-2 regulates alpha3beta1 integrin-dependent cell functions on laminin-5. J Cell Biol 2003, 163:1167-1177.
26. Zijlstra A., Lewis J., Degryse B., Stuhlmann H., Quigley J.P. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 2008, 13:221-234.
27. Kohno M., Hasegawa H., Miyake M., Yamamoto T., Fujita S. CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer 2002, 97:336-343.
28. Sadej R., Romanska H., Kavanagh D., Baldwin G., Takahashi T., Kalia N., et al. Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res 2010, 70:6059-6070.
29. Zhu G.H., Huang C., Qiu Z.J., Liu J., Zhang Z.H., Zhao N., et al. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci 2010, 56:1090-1098.
30. Ninomiya H., Hiramatsu M., Inamura K., Nomura K., Okui M., Miyoshi T., et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009, 63:235-240.
31. Hemler M.E. Targeting of tetraspanin proteins - potential benefits and strategies. Nat Rev Drug Discov 2008, 7:747-758.
32. Hua L.V., Green M., Wong A., Warsh J.J., Li P.P. Tetraspan protein CD151: a common target of mood stabilizing drugs. Neuropsychopharmacology 2001, 25:729-736.